| Dr. Holger Reithinger, Investment Director, 3i Dr Holger Reithinger is a Director of the 3i Germany’s Healthcare practice. From 1997 - 2000, he was an Investment Manager for Technologieholding VC GmbH. A leading German specialist early-stage technology fund in its days, it was acquired by 3i Germany in Feb 2000. He worked in industry as Product Development Manager with Biometra/Whatman PLC where he was responsible for the identification, development and marketing of new molecular biological products. He holds a PhD in Biochemistry, which he obtained on protein design under Prof Dr Hartmut Michel (Nobel Laureate 1988) at the Max-Planck-Institute of Biophysics, and as an undergraduate read Molecular Biology/Microbial Biology and Biochemistry at Universities of Heidelberg and Munich. Board seats held by Dr Reithinger now or in the past include 4SC AG, apovia AG, Switch Biotech AG, Epigenomics AG, Munich Biotech AG, Xerion Pharmaceuticals AG. |
 |
| Dr. Regina Hodits, Principal, Apax Partners Regina Hodits joined Apax Partners in October 2000 as a member of the healthcare team. Prior to this she worked at McKinsey & Company in the UK, Scandinavia, Germany and Eastern Europe, specialising on the biotech and pharmaceutical industry. During an eight month sabbatical, she held the position of COO of a Scandinavian biotech company. Previously, she worked for six years in medical research in Cambridge (UK), Spain and Austria, focusing on protein engineering and virology. Regina holds a PhD in Biochemistry, and an MSc in chemical engineering. |
 |
| Dr. Francois Thomas, Principal, Atlas Venture François Thomas joined Atlas Venture in 2001 as a Senior Consultant and is member of the board of 3 biotech companies. Previously, he was General Manager of Bioserve Ltd, a healthcare consultancy, Vice President (VP) of pharmacogenomics and licensing at Genset, a genomic company, and VP of clinical development at Ipsen Beaufour, a European pharmaceutical group. As a Medical Doctor, François practiced medical oncology as an Assistant Professor at the Gustave Roussy Institute in Paris and was also research fellow at the US National Cancer Institute. François received his MD from Paris School of Medicine, and a master of management from the Sloan School at MIT. |
 |
| Chris Piggott, Senior Director, Global Business Development, Aventis Chris has spent his entire career in Aventis and its predecessor companies since - a pharmacology graduate - joining May & Baker in the UK as a medical representative in 1974. The next part of his career was spent in commercial functions in the UK and internationally, until with the creation of Hoechst Marion Roussel in 1995 he became head of Strategic Marketing and Business Development in the UK. In 1998, Chris assumed responsibility in the HMR Global Business Development team, based in New Jersey, for relationships with Japanese companies, and he continued in this role with the formation of Aventis in 2000. During this period he was also responsible for providing licensing support to the anti-infective, and later the respiratory research groups. In 2002, Chris moved back to Europe and, based in Paris, assumed the role of supporting first the CNS research group, and more recently leading licensing efforts in the oncology area. Chris is also responsible for coordinating Aventis' product divestments, and from time to time for the negotiation of major licensing deals in other therapeutic areas. During his time in licensing, Chris has worked on deals with US, European and Japanese partners, and with biotech, mid-size and big pharmaceutical partners. |
 |
| Dr. Chris Henderson, Director Global Licensing, AstraZeneca Chris joined the pharmaceutical industry in 1980 when he left an academic post as a Lecturer in pharmacology and went to Pfizer Central Research in Sandwich, Kent. After 7 years with Pfizer, where latterly he was responsible for research programmes in the heart failure area, he moved to ICI Pharmaceuticals (which became part of Zeneca) at Alderley Park to initiate new cardiac research. In 1991, Chris changed role within research when he became responsible for scientific liaison and research collaborations, particularly in the cardiovascular and metabolism areas. This position entailed interaction with other Zeneca functions, such as commercial and medical, as well as the establishment and management of external research alliances with UK and US academic groups. Chris' next appointment was as Collaborations Manager within the TAG (Technology Access Group) – this group had been set up after a major review of Zeneca's strategy and R&D organisation, with the objective of establishing new R&D collaborations with Academia and the Biotech Industry. Chris joined Product Licensing at Zeneca in 1996 and is now responsible within AstraZeneca Global Licensing, as part of a dedicated "Japan Team", for interactions including deal-making with Japanese-based pharmaceutical companies across all therapy areas as well as acting as Global Transaction Manager (“deal-maker”) for the Cardiovascular Therapy Area. He has managed Licensing Teams responsible for deals of many different types with a wide range of partners. |
 |
| Prof. Dr. Jesper Zeuthen, Managing Director, BankInvest Bio Venture Jesper Zeuthen has been working for the BankInvest Group as a consultant since 1988, and he decided to join us full time in spring 2000 working primarily with venture capital. Previously, Jesper Zeuthen has worked as Head of R & D at Novo Nordisk and Head of Research at The Danish Cancer Society. He is the author of more than 200 publications in immunology, cell biology and molecular biology and served as adjunct professor of biotechnology at the University of Copenhagen. |
 |
| Heinz Michael Meier, Chief Executive, Bayern Kapital GmbH Heinz Michael Meier has been CEO of Bayern Kapital, a wholly owned subsidiary of LfA Förderbank Bayern, the Bavarian Bank for the Advancement of the economy, since the company's foundation in 1995. He is responsible for the management of Venture Capital Funds nearly totalling EUR 200 million. Bayern Kapital is managing its own fund as well as Seedfonds Bayern and Technofonds Bayern I and II. The main investment focus is early stage financing of enterprises in the field of biotechnology, IT, software and other key industrial technologies. Before his career as VC manager Mr. Meier served as Senior Vice President of Bayerische Landesbank's Equity Investment Division. He also held various positions in Bayerische Landesbank's Foreign Operations. As First Vice President of the Bank's International Network Division his responsibilities included the strategic orientation and the operational control of the Bank's foreign subsidiaries, branches and representative offices. He also served as First Head of Bayerische Landesbank's operations in Hungary and the Bavarian Government's Liaison Office in Budapest. Prior to his banking career Mr. Meier was a Senior Official in the Economic and Treasury Division of the Bavarian Ministry of Finance. He also held assignments in the Organization of Economic Cooperation and Development (OECD) in Paris and Munich University's Institute of Political Science and Public Law. Mr. Meier is Lecturer at Munich's Academy of Business Administration (VWA). His Memberships include the German Industry Association's Tönissteiner Kreis, Berlin. He also served as Industry and Commerce Representative on the Bavarian Tax Advisors' Examination Board. Mr. Meier pursued his professional studies at the Universities of Munich and Geneva and The London School of Economics and is a scholar of Studienstiftung des Deutschen Volkes (German National Scholarship Foundation). He earned his qualification as attorney with distinction in Munich. Postgraduate studies in the USA at George Washington University and the University of Illinois were honored with an M.C.L. Degree. |
 |
| Prof. Dr. Horst Domdey, CEO, Bio-M AG As well as holding the position of Managing Director & CEO at Bio-M AG, Prof. Dr. Horst Domdey is also Managing Director of the Innovation Centre for Biotechnology (IZB), Chairman of the Munich BioRegio Initiative and Co-founder of MediGene AG and Switch Biotech AG. He has vast experience in the field of Biochemistry having been a Postdoctoral fellow at numerous institutes including Max-Planck-Institut fur Biochemie, the Swiss Institute for Experimental Cancer Research (ISREC), University of California and the California Institute of Technology. Further to this, he was Associate Professor for Biochemistry at the Ludwig-Maximilians-Universitat Munchen for 4 years. |
 |
| Dr. Jonathan D. Turner, Head of Corporate Dept. Business Development, Boehringer Ingelheim After a brief academic career teaching in Psychiatry, Dr Turner joined industry with Schering AG managing drug discovery in CNS research for 10 years before joining Astra in 1997. At Astra and AstraZeneca he has fulfilled roles in collaboration and alliance management and inward licensing in multiple indications. Since late 2002 he has assumed responsibility for identification and evaluation of clinical phase in-licensing opportunities and potential alliances to support and extend the Boehringer Ingelheim portfolio. |
 |
| Spiro Rombotis, CEO, Cyclacel Spiro Rombotis, 44, joined Cyclacel in August 1997 as Chief Executive. Before Cyclacel he held senior positions at The Liposome Company, Inc. including Vice President, International Operations & Business Development, Managing Director of the European subsidiary in London and Director of a Japanese joint venture company. He was previously an executive with Bristol-Myers Squibb Company, most recently as Vice President, Pharmaceuticals, Central & Eastern Europe; Centocor, Inc., a leading biotechnology company, as head of European marketing and sales and head of corporate development; and Ciba-Geigy AG (now Novartis) in business development. Mr Rombotis read Economics and Sociology at Williams College, USA and received a MBA and a Master's degree in Hospital Administration with honours from Northwestern University’s Kellogg Graduate School of Management. |
 |
| Dr. Alexander Asam, Partner, DVC Deutsche Venture Capital Dr. Alexander Asam joined DVC as Partner in 2001. He has a long operational experience in various positions in the life science sector, both in multinational companies and in a biotech company. Among others things, he was part of the core team at LION bioscience AG preparing and executing a dual listing at NASDAQ and at the German Stock Exchange. Alexander received his Ph.D. in Chemistry from the University of Heidelberg and was afterwards granted an industry scholarship to conduct postdoctoral research work at the University of Amsterdam. In addition, he holds a Master of Business Administration (MBA) from Aston Business School, Birmingham. Alexander is a member of the supervisory board of
AVONTEC GmbH |
 |
| Dimitri F. Dimitriou, CEO, DyoDelta Biosceinces Ltd Dimitri F. Dimitriou, has over 17 years experience in healthcare in corporate transactions / business development, general management, marketing, sales, finance and R&D, both in the pharma and biotech sectors. He received his first degree in Biochemistry from the University of London prior to graduating in Pathology & Toxicology from the Royal Postgraduate Medical School in London in 1984. He began his career in the pharmaceutical industry as Product Manager in Marketing at Sandoz (Novartis) and was recruited in 1989 into Procter & Gamble, where he spent around 8 years in managerial positions including overall responsibility for Sales and Marketing for the pharmaceutical business in Asia, and later, Finance, Clinical Development of anti-infectives, and heading Medical Information prior to eventually concentrating in Licensing and Acquisitions as Business Development Manager-Europe. Dimitri joined SmithKline Beecham in 1996 as Associate Director and was appointed Director, Worldwide Business Development in 1998 and Senior Director in January 2000. His responsibilities included worldwide transactions - licensing deals, alliances and collaborations with pharmaceutical and biotech companies. In his role at SmithKline Beecham and GlaxoSmithKline, he routinely handled identification of opportunities, commercial assessment and due diligence, development of deal structures, and agreement negotiations. In 2001, he left GSK to move to the biotech sector as CEO of the London-based drug discovery company Xcellsyz and in addition set up DyoDelta Biosciences, a company providing support in licensing, corporate and financing transactions. In mid-2002, Dimitri joined Bristol-Myers Squibb setting up and heading the Business Development function in Europe, responsible for the full array of business development opportunities on a global basis with a focus on deals with European companies, before leaving a few months later to return to DyoDelta Biosciences. Dimitri has managed approx. 25 executed collaborations, having been involved in over 100 partnering projects over the past 8 years. He is a regular speaker in partnering conferences and also a member of the Convocation of the University of London, the Licensing Executives Society, the Pharmaceutical Licensing Group, British Mensa and the Chairman of the Advisory Board of Pharmalicensing. |
 |
| Dr. Marion Dörner, Principal, Earlybird GmbH & Co. KG Marion Dörner joined Earlybird in 1999 as an associate in the healthcare group. From the beginning, she was involved in building Earlybird´s healthcare portfolio in Europe and the US. With a broad and international network she actively helps our portfolio companies to accomplish their value-creating milestones, and has accompanied several portfolio companies from Earlybird’s initial investment through subsequent financing rounds (i.e. amaxa, Bernina and GMD). She also actively assisted a European merger involving a portfolio company. Marion’s interests are centered around innovative technologies and products that serve to increase the R&D productivity of the pharmaceutical value chain. She joined Earlybird after her postdoctoral training
in Molecular Biology at the Ludwig-Maximilians-University in Munich.
She earned her PhD under the supervision of Prof. Dr. Svante Pääbo
while working on genetic peculiarities of mammalian mitochondria.
She has gained further research expertise in programs at Arizona
State University in Phoenix, Arizona and at the Marine Marion received a Dipl.-Biol. (MS equivalent) from the Ludwig-Maximilians-University in Munich. She is author of several articles that were published in peer reviewed journals and serves on the board of EUROPROTEOME AG. |
 |
| Dr.
Olaf Bartsch, Vice President Business Development
Europe, Career development: 1992 until now different
responsibilities at Genzyme Corp. |
 |
| Dr. Hans A. Küpper, Partner, Global Life Science Ventures GmbH Dr. Hans Küpper has over 30 years of experience in the field of biotechnology in areas from research up to R&D management, technology assessment and business acquisitions. He received his PhD at the University of Heidelberg in 1974 and spent two years as a postdoctoral fellow at the Massachusetts Institute of Technology. After having worked for Biogen in Geneva, Dr Küpper joined Behringwerke AG to head its Molecular Biology Department. Since 1991, Dr. Küpper has been increasingly involved in deal negotiations and various aspects of company restructuring such as acquisitions, and early-stage and joint ventures. Dr. Küpper is the author of 48 publications and 13 patents/applications. He has served extensively as a consultant for the Pharmaceutical Industry and the European Commission. |
 |
| Hanns-Peter Wiese, Partner, Global Life Science Ventures GmbH Mr. Wiese has more than twelve years of experience in private equity and venture capital both on national and international levels. His exposure to early-stage investing in the life sciences reaches back to 1996, when he jointly set-up the predecessor fund. Since then he has been a Managing Director of Life Science Ventures, the fund advisor to the Global Life Science L.P. Prior to this, Mr Wiese was Director of Corporate Finance with Bayerische Vereinsbank in Munich and Director of their associate fund managed by Euro Synergies Management S.A. in Paris. Before that, Mr. Wiese was with 3i Group plc, first in the UK, then as Investment Manager in their Frankfurt office. Mr. Wiese has a masters degree in business administration from Hamburg University. He is responsible for the legal, financial and administrative affairs of the partnership. |
 |
| Chris Britten, Director, GSK Ventures, GlaxoSmithKline Chris Britten is a Director of GSK Ventures within
GlaxoSmithKline R&D. Prior to joining the group, Chris held a number of positions within early-stage R&D at GSK, leading both basic science and lead discovery programs in respiratory, anti-inflammatory and anti-viral therapeutic areas. Whilst at GlaxoWellcome, he lead the company’s exploration of opportunities within reproductive medicine. Chris holds a PhD in Biochemistry, from the Universities of York and Pennsylvania and an MBA (with distinction) from London Business School. |
 |
| Dr. Andreas Wicki, CEO, HBM Partners AG Dr. Wicki (43) is a successful healthcare entrepreneur and investor, and currently leads the management team of HBM BioVentures AG, one of the leading investment companies with a life sciences focus. He was co-owner and CEO of ANAWA Laboratorien AG, a healthcare analytical services company which was successfully sold in 1998 to MDS Inc. (NYSE MDZ; TSE MDS), a major healthcare services and clinical research organization with more than ten thousand employees. He was Senior Vice President of European Analytical Operations of MDS Pharma Services. He was also the founder and CEO of Clinserve AG, a rapidly growing clinical trial services company. Dr. Wicki has over 10 years of experience in the pharma and biotechnology industry and has been advising APAX and Bank Vontobel on their private equity investments in that sector since 1992. Dr. Wicki holds a Master of Science and a Ph.D. in chemistry and biochemistry from the University of Berne, Switzerland. Dr. Wicki is on the Board of Directors of the healthcare companies Basilea Pharmaceutica AG, Buchler GmbH, Cytos Biotechnology AG and MDS Pharma Services Switzerland AG. |
 |
| Neil Cohen, General Partner, Israel Seed Partners Neil Cohen is a General Partner of Israel Seed Partners,
a leading Prior to founding Israel Seed Partners, Neil was
vice president of sales |
 |
| Stan Yakatan, Chairman, Katan Associates After 30 years as a successful CEO, entrepreneur,and operational manager, Stan Yakatan has dedicated the last 7 years of his career to sharing his experiences with management teams interested in building technology based companies. His experience as an executive and in several instances serving as CEO with New England Nuclear, EI Dupont, ICN Pharma, New Brunswick Scientific and Biosearch, provided him with management and corporate finance acumen that he enjoys sharing with others. He has founded or co-founded in excess of 15 companies in the United States, Canada, Israel, France and Germany and in many cases served as the initial CEO, and Chairman of these companies. He currently sits on the board of directors of several public and private companies and has advised several of the world's leading venture capital firms including TVM (Germany), Ventana (USA), MSP (USA) and Biocapital (Canada). He has completed and advised on numerous acquisitions and corporate finance transactions raising in excess of $1.0 billion dollars in the public and private capital financing markets. He is a frequent speaker at financial and biotechnology conferences throughout the world speaking on topics including, "Capital Raising for the Technology-Based Start-Up" and "The Need to be Global in the Quest for Capital and Partners". Rick Biondi, Editor of Lab Business Magazine stated," Mr Yakatan is a venture capital raising Guru and it is part of his genetic make up." He currently serves as the strategic advisor to the state government of Victoria, Australia and is the Chairman of Katan Associates International with headquarters in New York City. |
 |
| Mark Clement, Chief Executive, Merlin Biosciences Limited A Chartered Accountant and Fellow of the Securities Institute Mark Clement has over 18 years corporate finance experience with PriceWaterhouse Coopers, ABN Amro, and more recently WestLB Panmure. In 1992 he was co-founder and Finance Director of Celsis International plc. He formed his own corporate finance consultancy in October 1997. He has extensive experience in negotiating and managing collaborations and consolidations both in the US and in Europe. He is an investment director of several Merlin portfolio companies. |
 |
| Adi Seffer, Partner, Morgan Lewis & Bockius LLP Adi Seffer is head of the Morgan Lewis Technology Practice in Frankfurt. His practice focuses on tech-driven transactions for Technology (TMT) - and Biotechnology clients and the financial community. He handles e-commerce matters, IP/IT and Biotech related agreements, M&A transactions and private and public financing. Mr. Seffer was nominated by Legal Media Group, London
as a leading lawyer in both Telecoms and IT, as one of only 30 lawyers
worldwide. Adi Seffer's transnational dispute experience includes ICC arbitration involving U.S. clients and other foreign clients, acting as a panel arbitrator in a German arbitration, and several ad hoc arbitrations under various German arbitration rules. His legal education in Regensburg, Frankfurt am Main and Munich was supplemented by training in International Law in London (1983), Comparison of Laws in Strasbourg, France (1984 and 1985), and International Investments in Barcelona, Spain (1989). Adi Seffer was President of the International Association of Young Lawyers (AIJA) (2001 - 2002). In addition, he is a member of the German Association for Intellectual Property Law (GRUR), of the Licensing Executives Society (LES) and of the German Association for Computer Law. Mr. Seffer is fluent in English, Spanish and French. He is admitted to the Frankfurt bar. |
 |
| Dr. Christian Zschocke, Managing Partner, Morgan Lewis & Bockius LLP Christian O. Zschocke is the managing partner of the Frankfurt office. His practice is concentrated in the areas of public takeovers as well as antitrust law. Dr. Zschocke is a regular speaker at seminars, and an author of numerous publications on corporate and antitrust law, including a commentary on the German Takeover Code and a handbook on the German Takeover Act. The publishers of Germany's leading antitrust review have turned to him as the editor responsible for the section on international antitrust developments. Prior to joining the firm in 1997, Christian Zschocke worked in the London, Brussels and Frankfurt offices of a New York-based international law firm. Dr. Zschocke also served as a trainee at the Commission of the European Communities, Directorate General IV for Competition, and for law firms in Barcelona, Buenos Aires, Hamburg and Paris. Dr. Zschocke has been appointed by the European Banking Federation and the Federation of European Stock Exchanges, to be one of six members of a European "Committee of Practitioners on Takeover Regulation" to contribute to the future European Takeover Directive as well as to serve as a platform for communication for the legislative process. Christian Zschocke is a German national. Dr. Zschocke is admitted to practice in Germany. He is admitted to the Bar of Cologne. In addition to a Dr. jur. from Hamburg University, Christian Zschocke is qualified as Licenciado en Derecho under Spanish Law. |
 |
| Dr. Ansbert Gadicke, Founding General Partner, MPM Capital Dr. Ansbert Gadicke is the Founding General Partner of the MPM Group. He led MPM's effort to build its Advisory and Investment Banking business from 1992 to 1996 and started its Asset Management business in 1996. Prior to founding MPM, Dr. Gadicke was employed by The Boston Consulting Group. Dr. Gadicke received an M.D. from J.W. Goethe University in Frankfurt. He subsequently held research positions in biochemistry and molecular biology at the Whitehead Institute at MIT, Harvard University and the German Cancer Research Center. He has published in leading scientific publications including Nature and Cell. Dr. Gadicke is Chairman of Elixir and a Director of Arriva, Endeavor Pharmaceuticals, Kourion, Idenix Pharmaceuticals, Omrix Biopharmaceuticals, Pharmasset, and ViaCell. He previously served as a Director of BioMarin, Coelacanth, MediGene and Transform. He is a member of Advisory Councils for Harvard Medical School, the Health Science and Technology Program of Harvard and MIT, as well as the Whitehead Institute at MIT. He serves as the Co-Chairman of the Alumni Association of the Whitehead Institute and serves on the Board of the National Venture Capital Association (NVCA). |
 |
| Dr.
Samir Master M.D., As Head of Global Search and Evaluation, Global Business Development and Licensing at Novartis AG, Samir Master is responsible for facilitating the initial evaluation and research for in-licensing compounds of biotech and specialty pharma companies, and overseas. In September 2002, Dr. Master joined Novartis and prior to his current position was responsible for identifying and evaluating in-licensing compounds for equity investments and M&A opportunities with biotechnology and specialty pharmaceuticals companies. Prior to joining Novartis, he was Entrepreneur-in-Residence at Bessemer Venture Partners. With over six years in venture capital financing, his strategic focus has been in investment opportunities for private biopharmaceutical, life sciences and medical device companies. Trained as an M.D., he completed post-graduate studies at University of Washington in Internal Medicine and at the University of Michigan in Dermatology. Dr. Master received his medical degree from Northwestern Medical School while completing his MBA at the Kellogg Graduate School of Management. Dr. Master is currently a member of the Board of Associates at MIT’s Whitehead Institute. |
 |
| Dr. Christoph H. Westphal, General Partner, Polaris Venture Partners Christoph H. Westphal is a general partner in our Boston office. Christoph joined Polaris in June 2000. He focuses on investment opportunities in medical technology and material science. Experience: Prior to joining Polaris, Christoph was at McKinsey & Co. in Boston and Los Angeles, working with high-growth biotech, pharmaceutical, materials science, wireless, and e-commerce companies. He was lead author on several papers published in Cell and Nature Genetics and is the inventor on two patents in the areas of cancer genetics and metabolic diseases. Boards: Christoph represents or has represented Polaris on the boards of directors of Advion BioSciences, Athenix Corp, Saegis Pharmaceuticals, eNOS Pharmaceuticals, Hydra BioSciences, and Nanosys. He was also founder and start-up CEO, and serves as vice chairman of both Momenta Pharmaceuticals, Inc. and Alnylam Pharmaceuticals. Education: Christoph completed his MD at Harvard Medical School and his PhD in genetics at Harvard University in six years. He majored in economics, literature, and biology while completing a BA summa cum laude and Phi Beta Kappa at Columbia University in three years. After graduating from Columbia, and prior to graduate schools, Christoph spent one year working with a medical team and studying in Cameroon and at the Albert Schweitzer Hospital in Africa, and worked for one year at a Max Planck Institute in Germany as a Fulbright/DAAD scholar. |
 |
| Frances Bornstein, Vice President, Head of Issuers and Investor Relations, SWX Swiss Exchange Frances Bornstein holds a degree in business management from Ludwig-Maximilians University in Munich. Following her studies, she was initially a consultant to the retailing industry. In 1996, she turned to business journalism, working as a television reporter and for an agency specialised in financial market news. She has been working for the SWX Swiss Exchange since December of 1998. |
 |
| Dr. Helmut M Schühsler, Managing Partner, Techno Venture Management Dr. Helmut M. Schühsler has been responsible for over 20 TVM investments in life science companies, and has since 1990 served on various committees, among others as a member of the senate of the Hermann von Helmholtz-Gemeinschaft Deutscher Forschungszentren (HGF). Currently he is a board member at the following life science companies: Curacyte AG, GPC Biotech AG, Ingenium Pharmaceuticals AG, Intercell AG, MediGene AG, Morphochem AG, Peptor Ltd, and SelectX Pharmaceuticals, Inc. Dr. Schühsler also is a member of the Supervisory Board of Garching Innovation GmbH, the technology transfer institution of the Max Planck Society, and of Ascenion GmbH, the technology transfer organisation of the HGF institutes GSF, GBF, and MDC. Prior to TVM, he was an Investment Manager at Horizonte Venture Management in Vienna. Dr. Schühsler wrote his doctoral thesis at the Economics University of Vienna in the area of business administration |
 |
| Michel Hubert, Vice President, Business Development, Transgene Michel HUBERT was appointed Vice-President, Business Development of Transgene in November 2001. Prior to joining Transgene, Michel HUBERT worked for eleven years for Laboratoires Fournier. As Fournier's Executive Director, Business Development & Licensing, he was responsible for creating and managing Fournier's Business Development and Licensing Department. Previously, he served as a Business Development Manager for Rhône-Poulenc Santé (now Aventis). Michel HUBERT is a graduate of the Strasbourg School of Pharmacy and holds a Master of Science in International Business from St Mary's College of California. |
 |
| Simon Sturge, Chief Executive Officer, Vernalis Simon Sturge became Chief Executive Officer of Vernalis plc following its merger in September 2003 with British Biotech plc. British Biotech plc completed a merger with RiboTargets Ltd in April 2003. Mr. Sturge founded RiboTargets when it was spun out from the Medical Research Council’s Laboratory of Molecular Biology in July 1997 with a £7 million venture capital investment. Having gained a degree in biology from Sussex University
in 1980, Mr. Sturge has spent more than twenty years in the pharmaceutical
industry in a variety of roles. After leaving university Mr. Sturge
became Product Manager of Napp Laboratories, Head of Sales and Marketing
at Smiths Industries and Business Development Manager at Astra Pharmaceuticals
before joining Celltech in 1988. Mr. Sturge was appointed Chief
Executive of Celltech Biologics plc (now Lonza Biologics plc) in
1995 where he remained for two years before joining RiboTargets
as Chief Executive. |
 |
| Nicholas J Lowcock, Managing Director, Warburg Pincus International LLC Nick Lowcock joined the Warburg Pincus Healthcare Group in 1994. Based in London, he is responsible for the firm’s European healthcare investment activities. This includes a portfolio with an estimated market value of around $1 billion and a rate of new investment averaging over $100 million per year. Mr. Lowcock spent the first four years of his career with Warburg Pincus in New York. He received an MBA (with distinction) from the Wharton School of the University of Pennsylvania and a BA (first class) in Experimental Psychology from Oxford University. His previous experience includes two years as a consultant at The Boston Consulting Group in New York and four years in the Pharmaceutical Industry in the United Kingdom. Mr. Lowcock currently serves on the board of directors of Leciva, Eurand, Strakan, Proskelia, Domus and PharmaIdea. He is also a trustee of Project Hope UK, a charity devoted to improving healthcare in developing nations. Mr. Lowcock is a member of the Executive Management Group of Warburg Pincus. |
 |
| N.
Peter Kostopulos, Partner, Womble
Carlyle Sandridge & Rice, PLLC N. Peter Kostopulos is Chairman of the Strategic Alliances Committee of the Licensing Executives Society (USA/Canada) and a partner in the Life Sciences Group of Womble Carlyle Sandridge & Rice, PLLC, a U.S. law firm of more than 450 lawyers. He represents private and public companies in a variety of R&D and commercial collaborations, and is particularly active in negotiating transatlantic transactions involving products and services in the United States and the European Union. Peter is considered an expert on strategic alliances, and has spoken at numerous U.S. and European conferences on a variety of topics, including negotiating R&D agreements, conducting due diligence, managing alliances to maximize return, dispute resolution, and the application of competition policy to intellectual property transactions. Peter has represented clients in judicial disputes involving breach of patent license agreements for failure to make best efforts, to report royalties, and to protect intellectual property, as well as cases alleging misappropriation of trade dress, trademark, and copyrights. He recently concluded a lawsuit brought against a European client by a prominent U.S. university alleging damages of $380 million for breach of multiple license agreements, which resulted in a favorable settlement for his client and established significant legal precedent regarding the U.S. enforcement of royalty agreements concerning non-U.S. patents. This experience provides clients with legal advice that reflects the business realities of international drug development, which facilitates communication with his clients and adverse parties and often optimizes the value of the deal. Peter is a graduate of the Georgetown University Law Center and Georgetown University, based in Washington D.C. Prior to entering private practice, he served as counsel for the Federal Trade Commission on competition law matters and as trial counsel for the Department of Justice, where he tried over 70 jury trials. In addition to his service as Chair of the U.S.-Canada LES Strategic Alliance Committee, he is a member of the American Bar Association’s Business Law and Intellectual Property Committees. In addition to English, Mr. Kostopulos speaks French and limited Greek. |
 |
| Ben Bronstein, Managing Director, Zero Stage Capital Dr. Bronstein joined Zero Stage Capital in 1999. He has responsibility for life sciences investing and advises portfolio companies on organizational, research and development, and business development issues, working closely with them from start-up through more advanced stages of development. Recently, he served as interim CEO of Spherics, a Zero Stage Capital portfolio company developing bioadhesive oral drug delivery systems. Dr. Bronstein has more than a decade of experience as a biotech entrepreneur, corporate executive, and advisor to biomedical and scientific companies. He was co-founder, president, and chief executive officer of Peptimmune, Inc., a venture capital financed biotechnology company developing immunotherapeutics, which was acquired by Genzyme in July 1999. Prior to Peptimmune, he was a senior executive with Seaflower Associates, Inc., a private equity advisory firm in Waltham, MA. From 1989-1993 Dr. Bronstein served as vice president of medical affairs and medical director of BioSurface Technology, Inc., which was acquired by Genzyme Corporation after an initial public offering. Dr. Bronstein began his career as a staff pathologist at the Massachusetts General Hospital and was on the faculty of Harvard Medical School. In addition to serving as a director on the boards of privately held life sciences companies, Dr. Bronstein is board member of Rhode Island’s Slater Center for Biomedical Technology. Dr. Bronstein received an A.B. in biology (magna cum laude), an MD degree, and an MBA (with high honors) all from Boston University. |
 |